Table 2.

In vitro and in vivo testing of immunoproteasome inhibitors in hematologic malignancies.

Inhibitor	Effective against	In Vitro/In Vivo Experiments	References
UK-101	MM	Patient samples	[150]
ONX-0914 (PR-957)	MM and MLLr-AML	Human cell lines Synergism with BTZ in a MM murine model	[99,127,136]
IPSI-001	MM, NHL, CLL, and AML	Human cell lines and patient samples	[44]
PR-924	MM, T-ALL, and AML	Human cell lines and patient samples MM xenograft model	[79,145]
LU-035i	MM	Human cell lines in conjugation with cytotoxic drug	[161]
HT2210 and HT2106	NHL	Human cell lines	[155]
M3258	MM, AML, and lymphoma	Human cell lines MM xenograft model Phase I clinical trial	[160,162,163]

MM: multiple myeloma; MLLr: MLL rearranged; AML: acute myeloid leukemia; NHL: non-Hodgkins lymphoma; CLL: chronic lymphocytic leukemia; T-ALL: T-cell acute lymphoblastic leukemia; BTZ: bortezomib.